1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 8, 26/Feb/2026
  4. Article
Perspective Open Access
Like 0
Download

Abstract

Annual reformulation and approval of seasonal influenza vaccines necessitate yearly evaluation of their effectiveness. Regulatory agencies, including the European Medicines Agency (EMA), rely on timely, real-world evidence to inform product-specific benefit-risk assessments. We explored the feasibility of conducting annual, brand-specific influenza vaccine effectiveness studies in Denmark, Finland and Sweden, starting with the 2024/25 season. These countries maintain population-wide vaccination, clinical and laboratory registers, linkable via personal identification numbers and updated in near real-time. We discuss suitable study designs and document that cohort studies using a target trial emulation (TTE) framework are feasible in all three countries; register-based test-negative case-control design (TND) studies are currently only feasible in Denmark. Supplementary methods, including regression discontinuity and negative control outcome analyses, can address residual bias. This Nordic collaboration has proven capacity for large-scale register-based studies and its infrastructure is able to address EMA’s requirements for timely, robust post-authorisation evidence to guide public health and regulatory decisions.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.8.2500648
2026-02-26
2026-03-07
/content/10.2807/1560-7917.ES.2026.31.8.2500648
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/8/eurosurv-31-8-4.html?itemId=/content/10.2807/1560-7917.ES.2026.31.8.2500648&mimeType=html&fmt=ahah

References

  1. European Medicines Agency (EMA). Guideline on influenza vaccines. Non-clinical and clinical module. Amsterdam: EMA; 2016. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/influenza-vaccines-non-clinical-and-clinical-module_en.pdf
  2. European Medicines Agency (EMA). Vaccine Monitoring Platform. [Accessed: 31 Jul 2025]. Amsterdam: EMA. Available from: https://www.ema.europa.eu/en/about-us/what-we-do/crisis-preparedness-management/vaccine-monitoring-platform
  3. Hviid A, Faksová K. Brand-specific influenza vaccine effectiveness in three Nordic countries. Feasibility assessment. Amsterdam: Heads of Medicines Agencies-European Medicine Agency Real-World Data (RWD) Catalogues; 2025. Available from: https://catalogues.ema.europa.eu/system/files/2025-02/Feasibility of IVE studies in Nordic settings_0.pdf
  4. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286.  https://doi.org/10.1136/bmj-2022-075286  PMID: 37491022 
  5. Husby A, Gulseth HL, Hovi P, Hansen JV, Pihlström N, Gunnes N, et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. BMJ Med. 2023;2(1):e000373.  https://doi.org/10.1136/bmjmed-2022-000373  PMID: 36936260 
  6. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022;7(6):600-12.  https://doi.org/10.1001/jamacardio.2022.0583  PMID: 35442390 
  7. Andersson NW, Thiesson EM, Pihlström N, Perälä J, Faksová K, Gram MA, et al. Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data. BMJ Med. 2024;3(1):e001074.  https://doi.org/10.1136/bmjmed-2024-001074  PMID: 39902239 
  8. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373(1114):n1114.  https://doi.org/10.1136/bmj.n1114  PMID: 33952445 
  9. Faksova K, Thiesson EM, Pihlström N, Baum U, Biering-Sørensen T, Poukka E, et al. Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data. Lancet Reg Health Eur. 2025;60:101518.  https://doi.org/10.1016/j.lanepe.2025.101518  PMID: 41255775 
  10. Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic health registry-based research: A review of health care systems and key registries. Clin Epidemiol. 2021;13:533-54.  https://doi.org/10.2147/CLEP.S314959  PMID: 34321928 
  11. Statens Serum Institut (SSI). Influenza – overvågning. [Influenza – surveillance]. Copenhagen: SSI. [Accessed: 13 Nov 2024]. Danish. Available from: https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/i/influenza-ugens-opgoerelse
  12. Grove Krause T, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. Euro Surveill. 2012;17(17):20155.  https://doi.org/10.2807/ese.17.17.20155-en  PMID: 22551494 
  13. Baum U, Sundman J, Jääskeläinen S, Nohynek H, Puumalainen T, Jokinen J. Establishing and maintaining the national vaccination register in Finland. Euro Surveill. 2017;22(17):30520.  https://doi.org/10.2807/1560-7917.ES.2017.22.17.30520  PMID: 28488994 
  14. Baum U, Ikonen N, Luomala O, Poukka E, Leino T, Nohynek H. Influenza Epidemiology in Finland During and After the COVID-19 Pandemic: Surveillance Data Analysis (2019-2024). Influenza Other Respir Viruses. 2025;19(6):e70131.  https://doi.org/10.1111/irv.70131  PMID: 40528677 
  15. Government Offices of Sweden. Ett samordnat vaccinationsarbete för effektivare hantering av kommande vacciner. [A coordinated vaccination effort for more effective management of upcoming vaccines]. Stockholm: Government Offices of Sweden; 2024. Swedish. Available from: https://regeringen.se/rattsliga-dokument/statens-offentliga-utredningar/2024/01/sou-20242/
  16. Li G, Gerlovin H, Figueroa Muñiz MJ, Wise JK, Madenci AL, Robins JM, et al. Comparison of the Test-negative Design and Cohort Design With Explicit Target Trial Emulation for Evaluating COVID-19 Vaccine Effectiveness. Epidemiology. 2024;35(2):137-49. . Available from: https://pubmed.ncbi.nlm.nih.gov/38109485/ https://doi.org/10.1097/EDE.0000000000001709  PMID: 38109485 
  17. European Medicines Agency (EMA). Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes. Amsterdam: EMA; 2025. Available from: https://www.ema.europa.eu/en/documents/other/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-regulatory-purposes_en.pdf
  18. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA. 2022;328(24):2446-7. . Available from: https://jamanetwork.com/journals/jama/fullarticle/2799678 https://doi.org/10.1001/jama.2022.21383  PMID: 36508210 
  19. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol. 2016;184(5):345-53.  https://doi.org/10.1093/aje/kww064  PMID: 27587721 
Feasibility of conducting brand-specific influenza vaccine effectiveness studies in three Nordic countries, Denmark, Finland, Sweden
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Kristyna+Faksova&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Faksova Kristyna</a>, <a href="/search?value1=Emilia+Myrup+Thiesson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Thiesson Emilia Myrup</a>, <a href="/search?value1=Nicklas+Pihlstr%C3%B6m&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pihlström Nicklas</a>, <a href="/search?value1=Ulrike+Baum&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Baum Ulrike</a>, <a href="/search?value1=Eero+Poukka&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Poukka Eero</a>, <a href="/search?value1=Tuija+Leino&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Leino Tuija</a>, <a href="/search?value1=Rickard+Ljung&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ljung Rickard</a>, <a href="/search?value1=Anders+Hviid&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hviid Anders</a></span>. Feasibility of conducting brand-specific influenza vaccine effectiveness studies in three Nordic countries, Denmark, Finland, Sweden. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(8):pii=2500648. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.8.2500648" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.8.2500648</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 20 Aug 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 18 Dec 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.8.2500648
/content/10.2807/1560-7917.ES.2026.31.8.2500648
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error